Intravenous
Glucagon Since the development of the radioimmunoassay of insulin, the measurement of plasma insulin has been essential in the diagnosis of insulinoma. Because of the wide deviation in fasting plasma insulin, the ratio of plasma insulin to blood glucose, rather than fasting plasma insulin, has been recommended as the parameter for the diagnosis of insulinoma (Grunt et al. 1970; Turner et al. 1971; Ohneda 1973 ). On the other hand, several provocation tests are performed for the diagnosis of the disease, since many factors are known to stimulate insulin secretion (Williams and Ensinck 1966) .
Glucagon was proved by Samols et al. (1965) to promote insulin secretion directly, and the glucagon test was widely employed in the diagnosis of insulinoma. However, there are a few reports in which the glucagon test is evaluated in comparison with other tests (Marks and Samols 1968; Vance et al. 1972 ). An intravenous glucagon test was carried out after an overnight fast. After a blood sample was drawn, 1 mg of crystalline glucagon (Beef-pork; Eli Lilly and Co. or pork; Novo Institute) in 2 ml of saline solution was injected intravenously within 30 sec. Blood samples were obtained from the ear lobe and the antecubital vein 1, 3, 6, 10, 15, 20, 30, 45 and 60 min after the glucagon injection. Furthermore, the glucose tolerance test (Goto et al. 1960 ), the tolbutamide test (Ohneda et al. 1974b ) and the arginine infusion test (Ohneda et al. 1972) were performed according to the methods described elsewhere. The results obtained in these tests were compared with the glucagon test.
RESULTS

Glueagon test
The blood glucose levels and the plasma insulin levels after the intravenous administration of glucagon are presented in Table 2 . The results in normal Insulin responses to these stimuli in the patients were compared in terms of insulin areas during these tests. The distribution of the insulin areas in each test is similar to those of the maximal levels of plasma insulin, as shown in Table 3 . The insulin areas in the glucagon test (0-30 min) exceeded the normal range in all except for 2 patients, whose insulin areas were in the upper range of the normal controls. The insulin areas in the glucose tolerance test were higher than the normal range in 10 out of 11 insulinomas. In the tolbutamide test, the insulin areas (0-30 min) were elevated in all the patients, except in the case of S.Y. who suffered so frequently from hypoglycemia that the tolbutamide test was not performed. The insulin areas in the arginine test (0-60 min) were increased in 5 patients, whereas those in the rest were within the normal range. patients (91%), as far as the maximal level of plasma insulin is concerned. The calculation of the insulin area during the glucagon test did not provide any superior recognition for insulinoma. Since the calculation of the insulin area is somewhat complicated, the maximal insulin level is recommended as a parameter for the diagnosis of insulinoma by the glucagon test.
There were a few reports in which the response of plasma insulin in the glucagon test was compared with that of other stimulants for insulin secretion in the patients with insulinoma. In this context, Marks and Samols (1968) and Vance et al. (1972) reported that the intravenous administration of glucagon rendered a better discrimination of the insulin response in insulinoma from the normal controls than the other provocation tests did . In the present study, fewer false negative cases were observed in the intravenous glucagon test than in the glucose test or the arginine infusion test. The fact that there was no significant correlation between the insulin response to glucagon and glucose, tolbutamide or arginine , points to a different mechanism for these stimulants to promote insulin secretion . It is interesting that the different responses of insulin to various stimulants were observed in the same patient, while the similar responses of plasma insulin to various stimuli were demonstrated in the normal controls. The difference might be interpreted by the difference of the morphological character of the tumor , such as the cell number or the cell type within the tumor and the character of the organelles of the tumor cells , as reported elsewhere (Ohneda et al. 1974a ).
The glucagon test has the following advantages: (1) better recognition of insulin response from the normal range, (2) no dangerous hypoglycemia during the test compared with the other provocation tests and (3) usefulness in the differential diagnosis of insulinoma from hypoglycemia due to the abnormalities in glycogenoly-tic pathway.
However, the glucagon test cannot always make a correct diagnosis of insulinoma, although the test is a useful tool . It is recommended from the present study that several tests to provocate insulin secretion should be combined, in addition to the glucagon test, and that the final diagnosis of insulinoma should be made by integrating all the results.
